⚠️
od kwietnia 2026 dostępne terapie: 1. L DRP → serplulimab + CTH; 1. L NDRP → atezolizumab (unfit DDP); amiwantamab + lazertynib, amiwantamab + CTH, enkorafenib+binimetynib
Terapie w programie lekowym:
Partner
Leki w katalogu chemioterapii:
Bleomycin Sulphate
Carboplatin
Cisplatinum
Cyklophosphamidum
Denosumab
Docetaxelum
Doxorubicinum
Epirubicinum
Erlotinibum
Etoposidum
Gefitynibum
Gemcitabine
Ifosfamidum
Irinotecanum
Lanreotidum
Methotrexatum
Nab-paclitaxel I.v.
Octreotidum
Paclitaxel
Pemetreksed
Temozolomidum
Topotecan P.o.
Topotecanum Inj.
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- lung cancer metastatic
- lung cancer adjuvant
- » AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)
- » A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs Investigator's Choice of Chemotherapy as Third-line Treatment in Advanced/Metastatic NSCLC
- » A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
- » A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
- » A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)